Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

NCT01290341 is registered in ClinicalTrials.gov with Merz North America, Inc. as lead sponsor.

NCT NCT01290341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01290341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
Lead sponsor
Merz North America, Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2011
Completion date
December 31, 2011
Enrollment
860 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

tinea pedis